Key facts
- Glyconics’s last known valuation is $9.0M (Jul 2025).
- It has raised $7.5M; the latest was Later Stage VC ($1.4M) in Jul 2025.
- Notable investors include Innovate UK, UK Research and Innovation, WCS Nominees, Anglia Capital Group, Boundary Capital Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Glyconics
- ·The full record, as it builds
Funding rounds
No funding rounds for Glyconics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glyconics
Manufacturer of medical diagnostics devices intended for early detection and monitoring of exacerbations and diseases. The company's device uses transform infrared spectroscopy to diagnose and monitor chronic and acute diseases, including respiratory diseases, and will identify spectral waves from samples, enabling doctors to analyze the composition of sputum samples for specific biomarkers and characteristics of chronic obstructive pulmonary disease in patients with suspected respiratory disease.
- Sector
- Healthcare
- HQ
- Colchester, United Kingdom
- Founded
- 2013
- Employees
- 4
- Website
- glyconics.com/
- Ownership
- Privately Held (backing)
Glyconics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glyconics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glyconics in its N-PORT filings yet. We sweep new filings monthly.